Green Cross aims to expand its plasma derivatives business by penetrating into the North American market, the world’s largest plasma derivatives market which accounts for 40% of the world's total market. Stonebridge Capital has invested CAD 70 million in Green Cross Biotherapeutics' CAD 316 million project for the construction of its new plasma derivatives plant in Quebec, Canada.

Through this investment, Green Cross aims to position the company as a dominant regional player and enter into the global top 7th manufacturer in the plasma derivatives market. Strong market demands in North America as well as the staunch track record of Green Cross led Stonebridge to proceed with the investment in the vehicle of preferred shares.

Currently, the construction of Green Gross Biotherapeutics’ plasma derivative plant in Canada has been completed in October 2017, and Stonebridge Capital is following up on the clinical trial process of plasma derivative pipelines.